Success Metrics

Clinical Success Rate
92.3%

Based on 24 completed trials

Completion Rate
92%(24/26)
Active Trials
0(0%)
Results Posted
96%(23 trials)
Terminated
2(8%)

Phase Distribution

Ph phase_2
3
12%
Ph phase_1
18
69%
Ph phase_3
4
15%

Phase Distribution

18

Early Stage

3

Mid Stage

4

Late Stage

Phase Distribution25 total trials
Phase 1Safety & dosage
18(72.0%)
Phase 2Efficacy & side effects
3(12.0%)
Phase 3Large-scale testing
4(16.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

92.3%

24 of 26 finished

Non-Completion Rate

7.7%

2 ended early

Currently Active

0

trials recruiting

Total Trials

26

all time

Status Distribution
Completed(24)
Terminated(2)

Detailed Status

Completed24
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
26
Active
0
Success Rate
92.3%
Most Advanced
Phase 3

Trials by Phase

Phase 118 (72.0%)
Phase 23 (12.0%)
Phase 34 (16.0%)

Trials by Status

terminated28%
completed2492%

Recent Activity

0 active trials
Showing 5 of 26
terminatedphase_3

A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

NCT04396236
terminatedphase_3

A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

NCT04396574
completed

Ditan Acute tReatments: Effectiveness and Tolerability (DART)

NCT05903040
completedphase_1

A Study of Lasmiditan in Healthy Volunteers

NCT04749914
completedphase_1

A Study to Compare Two Different Formulations of Lasmiditan in Healthy Participants

NCT04881747
View all 26 trials

Clinical Trials (26)

Showing 20 of 26 trialsScroll for more
NCT04396236Phase 3

A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Terminated
NCT04396574Phase 3

A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Terminated
NCT05903040

Ditan Acute tReatments: Effectiveness and Tolerability (DART)

Completed
NCT04749914Phase 1

A Study of Lasmiditan in Healthy Volunteers

Completed
NCT04881747Phase 1

A Study to Compare Two Different Formulations of Lasmiditan in Healthy Participants

Completed
NCT03670810Phase 3

A Study of Lasmiditan (LY573144) Over Four Migraine Attacks

Completed
NCT04081324Phase 1

A Study of Lasmiditan in Healthy Chinese Participants

Completed
NCT03962738Phase 2

A Study Lasmiditan (LY573144) in a Single Migraine Attack in Japanese Participants With Migraine

Completed
NCT03988088Phase 1

A Study of Lasmiditan (LY573144) in Children Aged 6 to 17 With Migraine

Completed
NCT02565186Phase 3

An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine

Completed
NCT03465436Phase 1

A Study of Lasmiditan on the Heart in Healthy Participants

Completed
NCT03459612Phase 1

A Study of Lasmiditan on Simulated Driving Performance in Healthy Participants

Completed
NCT03252015Phase 1

A Study of Multiple Doses of Lasmiditan in Healthy Participants

Completed
NCT03286218Phase 1

A Study of the Abuse Potential of Lasmiditan in Participants Who Are Recreational Drug Users

Completed
NCT03012334Phase 1

The Effects of Lasmiditan on Simulated Driving Performance - Healthy Participants

Completed
NCT03182920Phase 1

A Study of Lasmiditan in Healthy Participants

Completed
NCT00883051Phase 2

Dose-ranging Study of Oral COL-144 in Acute Migraine Treatment

Completed
NCT03270644Phase 1

A Study of Lasmiditan and Propranolol in Healthy Participants

Completed
NCT03247790Phase 1

A Study of Lasmiditan in Participants With Migraine

Completed
NCT03009162Phase 1

Study of Oral Lasmiditan in Participants With Normal and Impaired Renal Function

Completed

Drug Details

Intervention Type
DRUG
Total Trials
26